Ophthotech Corporation (NASDAQ:OPHT) dropped -1.92% or -1.08 points to trade at $55.25 per share. As per the latest trading data available, the net money flow stood at $0.65 million as the shares received $2.12 million in upticks and gave away $1.47 million in downticks. The final up/down ratio was at 1.45. On a weekly basis, the stock has seen a change of -2.76%.During the course of the session, the shares witnessed a block trade with an up/down ratio of 0. $0.92 million was the inflow in upticks and $0 million was the outflow in downticks. For the block trade, the net money flow was $0.92 million.
Currently the company Insiders own 12.2% of Ophthotech Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -26.17% . Institutional Investors own 90.6% of Ophthotech Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -26.65%. On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Ophthotech Corp., Bolte Axel had purchased shares worth of $199,395 in a transaction dated on June 3, 2016. A total of 3,500 shares were purchased at a price of $56.97 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Ophthotech Corporation (NASDAQ:OPHT) stock ended Monday session in the red zone in a volatile trading. The stock closed down 2.54 points or 4.51% at $53.79 with 478,485 shares getting traded. Post opening the session at $56.11, the shares hit an intraday low of $53.77 and an intraday high of $56.69 and the price was in this range throughout the day. The company has a market cap of $1,903 million and the number of outstanding shares have been calculated to be 35,370,681 shares. The 52-week high of Ophthotech Corporation (NASDAQ:OPHT) is $80 and the 52-week low is $35.72.
Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm JP Morgan upgrades its rating on Ophthotech Corporation (NASDAQ:OPHT). The rating major has initiated the coverage with overweight rating on the shares. Earlier, the shares were rated a Neutral by the brokerage firm. The Analysts at JP Morgan raises the price target from $60 per share to $84 per share. The rating by the firm was issued on June 2, 2016.
Ophthotech Corporation is a United States-based biopharmaceutical company. The Company is engaged in developing and commercializing therapies for the treatment of diseases of the eye and focuses on developing therapeutics for age-related macular degeneration (AMD). Its product pipeline includes Fovista anti-platelet derived growth factor (PDGF) therapy, which is in Phase III clinical trials for use in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. It prevents PDGF from binding to its natural receptor on pericytes, thus causing pericytes to be stripped from newly formed abnormal blood vessels.Its second product candidate, Zimura, an inhibitor of complement factor C5, is developed for the treatment of geographic atrophy (a form of dry AMD) and, in combination with anti-VEGF therapy and Fovista, for the treatment of wet AMD. Both Fovista and Zimura are aptamers, single strands of nucleic acid that binds with affinity to targets.